quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:08:40·808d
NEWSRelease
Chenghe Acquisition Co. logo
DMK Pharmaceuticals Corporation logo
Everbridge Inc. logo
+3

Gold Moves Lower; ISM Services PMI Beats Estimates

CHEA· Chenghe Acquisition Co.DMK· DMK Pharmaceuticals CorporationEVBG· Everbridge Inc.FDMT· 4D Molecular Therapeutics Inc.NSTG· NanoString Technologies Inc.PEGY· Pineapple Energy Inc.
FinanceHealth CareTechnology
Original source

Companies

  • CHEA
    Chenghe Acquisition Co.
    Finance
  • DMK
    DMK Pharmaceuticals Corporation
    Health Care
  • EVBG
    Everbridge Inc.
    Technology
  • FDMT
    4D Molecular Therapeutics Inc.
    Health Care
  • NSTG
    NanoString Technologies Inc.
    Health Care
  • PEGY
    Pineapple Energy Inc.
    Utilities

Recent analyst ratings

  • Jan 28FDMTUpdateBarclays$33.00
  • Nov 7FDMTUpdateMorgan Stanley-
  • Jan 13FDMTUpdateBMO Capital Markets$15.00
  • Nov 21FDMTUpdateMorgan Stanley$8.00
  • Sep 23FDMTUpdateCantor Fitzgerald-
  • Apr 15FDMTUpdateBarclays$45.00

Related

  • PR6d
    4DMT Announces New Employment Inducement Grants
  • SEC16d
    Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
  • SEC24d
    4D Molecular Therapeutics Inc. filed SEC Form 8-K: Leadership Update
  • INSIDER27d
    SEC Form 4 filed by Simms Christopher Paul
  • INSIDER27d
    SEC Form 4 filed by Kirn David
  • INSIDER27d
    SEC Form 4 filed by Bizily Scott
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.
  • INSIDER30d
    SEC Form 4 filed by Gupta Ashoo
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022